JUST IN: Soleno Therapeutics nears a 2.5B acquisition by Neurocrine, with shares potentially valued in the low-to-mid 50s per the Financial Times.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin